Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases

Enrico Balleari, Riccardo Ghio, Antonietta Falcone, Pellegrino Musto

Research output: Contribution to journalArticle

Abstract

Thalidomide has been shown to be effective in approximately 30% of patients with refractory or advanced multiple myeloma (MM). Here we report on 4 cases of patients treated with thalidomide for refractory MM showing dedifferentiation of the neoplasm. In these cases thalidomide treatment - despite reduction of M-component - was followed by disease progression and a very poor clinical outcome which was paralleled by bone marrow plasmacytosis showing marked signs of dedifferentiation, inducing us to speculate on a potential role of thalidomide on dedifferentiation of myeloma cells. In our opinion, a possible dedifferentiation of MM should therefore be taken into account in MM patients treated with thalidomide when clinical course deteriorates despite reduction of M-component.

Original languageEnglish
Pages (from-to)735-738
Number of pages4
JournalLeukemia and Lymphoma
Volume45
Issue number4
DOIs
Publication statusPublished - Apr 2004

Keywords

  • Dedifferentiation
  • Extramedullary plasmacytoma
  • M-component
  • Multiple myeloma
  • Plasmacells
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases'. Together they form a unique fingerprint.

  • Cite this